Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
BMC Infect Dis ; 21(1): 599, 2021 Jun 23.
Article in English | MEDLINE | ID: mdl-34162344

ABSTRACT

BACKGROUND: Gastrointestinal illness is a major cause of morbidity in travellers and is a common reason for presentation to healthcare services on return. Whilst the aetiology of imported gastrointestinal disease is predominantly infectious, outcomes are variable due to a range of phenomena such as post-infectious irritable bowel syndrome, drug resistance and occult pathology (both infectious and non-infectious). Previous studies have focussed on predictors of aetiology of gastrointestinal disease in travellers; we present a retrospective study combining both aetiological and early outcome data in a large cohort of returned travellers. METHOD: We identified 1450 patients who attended our post-travel walk-in clinic with gastrointestinal symptoms between 2010 and 2016. Demographic, travel, clinical and laboratory data was collected through case note review. Logistic regression analysis to examine correlates of aetiology and outcome were performed in R (CRAN Project 2017). RESULTS: Of 1450 patients in our cohort 153 reported bloody diarrhoea and 1081 (74.6%) reported non-bloody diarrhoea. A definitive microbiological diagnosis was made in 310 (20.8%) of which 137 (9.4%) had a parasite identified and 111 (7.7%) had a bacterial cause identified. Factors associated with a parasitological diagnosis included history of travel to South Asia (aOR = 2.55; 95%CI 1.75-3.70, p < 0.0001) and absence of bloody diarrhoea (aOR = 0.22; 95%CI 0.066-0.53, p < 0.005). Factors associated with a bacteriological diagnosis included male gender (aOR = 1.69; 95%CI 1.10-2.62, p < 0.05), an age < 37 years on presentation (aOR = 2.04; 95%CI 1.25-3.43, p < 0.01), white cells on stool microscopy (aOR = 3.52; 95%CI 2.09-5.86, p < 0.0001) and a C-reactive protein level of >5iu/dL (aOR = 4.68; 95%CI 2.91-7.72, p < 0.0001). The majority (1235/1450, 82.6%) reported full symptomatic resolution by the first follow up visit; factors associated with lack of symptomatic resolution included female gender (aOR = 1.45 95%CI 1.06-1.99, p < 0.05), dysenteric diarrhoea (aOR = 2.14 (95%CI 1.38-3.25, p < 0.0005) and elevated peripheral leukocyte count (aOR = 1.58 95%CI 1.02-2.40, p < 0.05). CONCLUSIONS: In a cohort of returned travellers, we were able to identify multiple factors that are correlated with both aetiology and outcome of imported gastrointestinal syndromes. We predict these data will be valuable in the development of diagnostic and therapeutic pathways for patients with imported gastrointestinal infections.


Subject(s)
Gastrointestinal Diseases/diagnosis , Gastrointestinal Diseases/etiology , Gastrointestinal Diseases/microbiology , Gastrointestinal Diseases/parasitology , Travel , Abdominal Pain/complications , Adult , Aged , Cohort Studies , Diarrhea/diagnosis , Diarrhea/etiology , Diarrhea/microbiology , Diarrhea/parasitology , Female , Humans , Male , Middle Aged , Retrospective Studies
2.
BMJ Open ; 10(11): e040216, 2020 11 26.
Article in English | MEDLINE | ID: mdl-33243801

ABSTRACT

OBJECTIVES: To describe a cohort of self-isolating healthcare workers (HCWs) with presumed COVID-19. DESIGN: A cross-sectional, single-centre study. SETTING: A large, teaching hospital based in Central London with tertiary infection services. PARTICIPANTS: 236 HCWs completed a survey distributed by internal staff email bulletin. 167 were women and 65 men. MEASURES: Information on symptomatology, exposures and health-seeking behaviour were collected from participants by self-report. RESULTS: The 236 respondents reported illness compatible with COVID-19 and there was an increase in illness reporting during March 2020 Diagnostic swabs were not routinely performed. Cough (n=179, 75.8%), fever (n=138, 58.5%), breathlessness (n=84, 35.6%) were reported. Anosmia was reported in 42.2%. Fever generally settled within 1 week (n=110/138, 88%). Several respondents remained at home and did not seek formal medical attention despite reporting severe breathlessness and measuring hypoxia (n=5/9, 55.6%). 2 patients required hospital admission but recovered following oxygen therapy. 84 respondents (41.2%) required greater than the obligated 7 days off work and 9 required greater than 3 weeks off. CONCLUSION: There was a significant increase in staff reporting illness compatible with possible COVID-19 during March 2020. Subsequent serology studies at the same hospital study site have confirmed sero-positivity for COVID-19 up to 45% by the end of April 2020 in frontline HCWs. The study revealed a concerning lack of healthcare seeking in respondents with significant red flag symptoms (severe breathlessness, hypoxia). This study also highlighted anosmia as a key symptom of COVID-19 early in the pandemic, prior to this symptom being more widely recognised as a feature of COVID-19.


Subject(s)
COVID-19/epidemiology , Health Behavior , Health Facilities/statistics & numerical data , Health Personnel/psychology , Pandemics , SARS-CoV-2 , Adolescent , Adult , Aged , Cross-Sectional Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Time Factors , United Kingdom/epidemiology , Young Adult
3.
Br Med Bull ; 117(1): 95-106, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26872858

ABSTRACT

BACKGROUND: The West African Ebola crisis of 2013-15 is the largest outbreak since Ebola was first identified; Ebola has high case fatality. SOURCES OF DATA: Pubmed with terms 'Ebola' and 'EVD' from January 1976 to June 2015. Public domain material. AREAS OF AGREEMENT: The emergence of Ebola virus, virology, clinical features and the major elements of the 2014 outbreak and the public health response. Ebola is only transmitted by direct contact with infected individuals (including dead bodies) and their body fluids. Methods of control in hospitals and burials, and protection of healthcare workers are well established if difficult to achieve. AREAS OF CONTENTION: There remains uncertainty surrounding specific public health interventions and novel therapies (including vaccines). How best to reduce transmission in the community during major outbreaks remains unclear. FUTURE DIRECTIONS: The potential of vaccine and therapeutic candidates in the event of another outbreak on this scale. . SEARCH STRATEGY: We searched all entries on the MedLine database/PubMed from 1976-2015 with the MeSH terms 'ebola', 'EVD', 'haemorrhagic fever'. We also reviewed publically available information via institutional websites from Governmental, NGOs and news organizations pertaining to the above search terms.


Subject(s)
Disease Outbreaks/prevention & control , Hemorrhagic Fever, Ebola/epidemiology , Africa, Western/epidemiology , Ebolavirus/pathogenicity , Hemorrhagic Fever, Ebola/prevention & control , Hemorrhagic Fever, Ebola/transmission , Humans , Public Health Administration
4.
Cell Calcium ; 58(6): 577-88, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26434503

ABSTRACT

Rises in cytosolic Ca(2+) concentration ([Ca(2+)]cyt) are central in platelet activation, yet many aspects of the underlying mechanisms are poorly understood. Most studies examine how experimental manipulations affect agonist-evoked rises in [Ca(2+)]cyt, but these only monitor the net effect of manipulations on the processes controlling [Ca(2+)]cyt (Ca(2+) buffering, sequestration, release, entry and removal), and cannot resolve the source of the Ca(2+) or the transporters or channels affected. To investigate the effects of protein kinase C (PKC) on platelet Ca(2+) signalling, we here monitor Ca(2+) flux around the platelet by measuring net Ca(2+) fluxes to or from the extracellular space and the intracellular Ca(2+) stores, which act as the major sources and sinks for Ca(2+) influx into and efflux from the cytosol, as well as monitoring the cytosolic Na(+) concentration ([Na(+)]cyt), which influences platelet Ca(2+) fluxes via Na(+)/Ca(2+) exchange. The intracellular store Ca(2+) concentration ([Ca(2+)]st) was monitored using Fluo-5N, the extracellular Ca(2+) concentration ([Ca(2+)]ext) was monitored using Fluo-4 whilst [Ca(2+)]cyt and [Na(+)]cyt were monitored using Fura-2 and SFBI, respectively. PKC inhibition using Ro-31-8220 or bisindolylmaleimide I potentiated ADP- and thrombin-evoked rises in [Ca(2+)]cyt in the absence of extracellular Ca(2+). PKC inhibition potentiated ADP-evoked but reduced thrombin-evoked intracellular Ca(2+) release and Ca(2+) removal into the extracellular medium. SERCA inhibition using thapsigargin and 2,5-di(tert-butyl) l,4-benzohydroquinone abolished the effect of PKC inhibitors on ADP-evoked changes in [Ca(2+)]cyt but only reduced the effect on thrombin-evoked responses. Thrombin evokes substantial rises in [Na(+)]cyt which would be expected to reduce Ca(2+) removal via the Na(+)/Ca(2+) exchanger (NCX). Thrombin-evoked rises in [Na(+)]cyt were potentiated by PKC inhibition, an effect which was not due to altered changes in non-selective cation permeability of the plasma membrane as assessed by Mn(2+) quench of Fura-2 fluorescence. PKC inhibition was without effect on thrombin-evoked rises in [Ca(2+)]cyt following SERCA inhibition and either removal of extracellular Na(+) or inhibition of Na(+)/K(+)-ATPase activity by removal of extracellular K(+) or treatment with digoxin. These data suggest that PKC limits ADP-evoked rises in [Ca(2+)]cyt by acceleration of SERCA activity, whilst rises in [Ca(2+)]cyt evoked by the stronger platelet activator thrombin are limited by PKC through acceleration of both SERCA and Na(+)/K(+)-ATPase activity, with the latter limiting the effect of thrombin on rises in [Na(+)]cyt and so forward mode NCX activity. The use of selective PKC inhibitors indicated that conventional and not novel PKC isoforms are responsible for the inhibition of agonist-evoked Ca(2+) signalling.


Subject(s)
Blood Platelets/metabolism , Calcium Signaling , Calcium/metabolism , Protein Kinase C/metabolism , Adenosine Diphosphate/metabolism , Blood Platelets/drug effects , Calcium Channels/metabolism , Calcium Signaling/drug effects , Cell Membrane/metabolism , Cytosol/metabolism , Humans , Indoles/pharmacology , Isoenzymes/metabolism , Platelet Activation/drug effects , Platelet Aggregation Inhibitors/pharmacology , Protein Isoforms/metabolism , Protein Kinase C/genetics , Thrombin/metabolism
5.
J Formos Med Assoc ; 110(6): 350-62, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21741003

ABSTRACT

Human immunodeficiency virus (HIV), the causative agent of AIDS, is a retrovirus. It is estimated that, while in the cell, it interacts with almost 10% of cellular proteins. Several of these have evolved to protect the cell from infection with retroviruses and are known as "restriction factors". Restriction factors tell us much about how the virus functions and open up new paradigms for exploring novel antiviral therapeutics. This article gives an update on the three best studied restriction factors, their putative mechanisms of action and how the virus has overcome their effects, together with an indication of novel therapeutic approaches based on this knowledge.


Subject(s)
Acquired Immunodeficiency Syndrome , Antiviral Agents , HIV , Immunity, Innate/genetics , APOBEC Deaminases , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/metabolism , Acquired Immunodeficiency Syndrome/virology , Antigens, CD/metabolism , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Antiviral Restriction Factors , Capsid/metabolism , Carrier Proteins/metabolism , Clinical Trials as Topic , Cytidine Deaminase , Cytosine Deaminase/metabolism , GPI-Linked Proteins/metabolism , Genes, vif , Genome-Wide Association Study , HIV/drug effects , HIV/genetics , HIV/physiology , Humans , Tripartite Motif Proteins , Ubiquitin-Protein Ligases , Virus Replication/drug effects , Virus Replication/genetics
6.
PLoS One ; 4(12): e8390, 2009 Dec 22.
Article in English | MEDLINE | ID: mdl-20027307

ABSTRACT

BACKGROUND: Expression of the minor virion structural protein VP2 of the calicivirus murine norovirus (MNV) is believed to occur by the unusual mechanism of termination codon-dependent reinitiation of translation. In this process, following translation of an upstream open reading frame (ORF) and termination at the stop codon, a proportion of 40S subunits remain associated with the mRNA and reinitiate at the AUG of a downstream ORF, which is typically in close proximity. Consistent with this, the VP2 start codon (AUG) of MNV overlaps the stop codon of the upstream VP1 ORF (UAA) in the pentanucleotide UAAUG. PRINCIPAL FINDINGS: Here, we confirm that MNV VP2 expression is regulated by termination-reinitiation and define the mRNA sequence requirements. Efficient reintiation is dependent upon 43 nt of RNA immediately upstream of the UAAUG site. Chemical and enzymatic probing revealed that the RNA in this region is not highly structured and includes an essential stretch of bases complementary to 18S rRNA helix 26 (Motif 1). The relative position of Motif 1 with respect to the UAAUG site impacts upon the efficiency of the process. Termination-reinitiation in MNV was also found to be relatively insensitive to the initiation inhibitor edeine. CONCLUSIONS: The termination-reinitiation signal of MNV most closely resembles that of influenza BM2. Similar to other viruses that use this strategy, base-pairing between mRNA and rRNA is likely to play a role in tethering the 40S subunit to the mRNA following termination at the VP1 stop codon. Our data also indicate that accurate recognition of the VP2 ORF AUG is not a pre-requisite for efficient reinitiation of translation in this system.


Subject(s)
Norovirus/metabolism , Peptide Chain Initiation, Translational , Peptide Chain Termination, Translational , Viral Proteins/metabolism , 5' Flanking Region/genetics , Animals , Base Sequence , Codon, Initiator/genetics , Codon, Terminator/genetics , Edeine/pharmacology , Luciferases/metabolism , Mice , Molecular Sequence Data , Norovirus/drug effects , Nucleic Acid Conformation , Nucleotides/genetics , Peptide Chain Initiation, Translational/drug effects , Peptide Chain Termination, Translational/drug effects , RNA, Complementary/genetics , RNA, Messenger/genetics , RNA, Ribosomal, 18S/genetics , RNA, Viral/chemistry , RNA, Viral/genetics , Regulatory Sequences, Nucleic Acid/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...